| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1013740220 |
| P356 | DOI | 10.1186/S40478-015-0201-7 |
| P932 | PMC publication ID | 4382927 |
| P698 | PubMed publication ID | 25853389 |
| P5875 | ResearchGate publication ID | 274727517 |
| P50 | author | Till Milde | Q52148375 |
| Thomas Hielscher | Q87639824 | ||
| Andrey Korshunov | Q89166780 | ||
| Andreas E Kulozik | Q89170845 | ||
| Ina Oehme | Q89280944 | ||
| Marcel Kool | Q90637389 | ||
| Hedwig E Deubzer | Q91874143 | ||
| Florian Selt | Q100479794 | ||
| Olaf Witt | Q114408281 | ||
| Jonas Ecker | Q114726918 | ||
| Marco Lodrini | Q114727046 | ||
| Stefan M. Pfister | Q39183179 | ||
| Andreas von Deimling | Q40381084 | ||
| P2093 | author name string | Judit Kiss | |
| Ralph Mazitschek | |||
| Carina Konrad | |||
| P2860 | cites work | Drug development: Raise standards for preclinical cancer research | Q22348097 |
| Signal-dependent nuclear export of a histone deacetylase regulates muscle differentiation | Q24290523 | ||
| Association with class IIa histone deacetylases upregulates the sumoylation of MEF2 transcription factors | Q24519076 | ||
| Molecular subgroups of medulloblastoma: the current consensus | Q24615271 | ||
| Dissecting the genomic complexity underlying medulloblastoma | Q24621907 | ||
| Histone Deacetylase (HDAC) Inhibitor Kinetic Rate Constants Correlate with Cellular Histone Acetylation but Not Transcription and Cell Viability | Q27679266 | ||
| Genome sequencing of SHH medulloblastoma predicts genotype-related response to smoothened inhibition | Q27852966 | ||
| Association of COOH-terminal-binding protein (CtBP) and MEF2-interacting transcription repressor (MITR) contributes to transcriptional repression of the MEF2 transcription factor | Q28140525 | ||
| Outcome prediction in pediatric medulloblastoma based on DNA copy-number aberrations of chromosomes 6q and 17q and the MYC and MYCN loci | Q28236937 | ||
| Subgroup-specific structural variation across 1,000 medulloblastoma genomes | Q28271811 | ||
| Integrative genomic analysis of medulloblastoma identifies a molecular subgroup that drives poor clinical outcome | Q28298987 | ||
| Mechanism for nucleocytoplasmic shuttling of histone deacetylase 7 | Q28594917 | ||
| Believe it or not: how much can we rely on published data on potential drug targets? | Q29547529 | ||
| Anticancer activities of histone deacetylase inhibitors | Q29616624 | ||
| Medulloblastoma exome sequencing uncovers subtype-specific somatic mutations | Q30040534 | ||
| CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007-2011. | Q30402063 | ||
| Chemical phylogenetics of histone deacetylases | Q30977637 | ||
| Early phase II trial of oral vorinostat in relapsed or refractory breast, colorectal, or non-small cell lung cancer | Q33379343 | ||
| Lack of therapeutic effect of the histone deacetylase inhibitor vorinostat in patients with metastatic radioiodine-refractory thyroid carcinoma | Q33381498 | ||
| A phase 2 study of intravenous panobinostat in patients with castration-resistant prostate cancer | Q33408846 | ||
| HR23B is a biomarker for tumor sensitivity to HDAC inhibitor-based therapy | Q33778769 | ||
| Drug-target residence time: critical information for lead optimization. | Q34054343 | ||
| A phase I, pharmacokinetic, and pharmacodynamic study of two schedules of vorinostat in combination with 5-fluorouracil and leucovorin in patients with refractory solid tumors | Q34099365 | ||
| Delineation of two clinically and molecularly distinct subgroups of posterior fossa ependymoma | Q34132926 | ||
| Molecular subgroups of medulloblastoma: an international meta-analysis of transcriptome, genetic aberrations, and clinical data of WNT, SHH, Group 3, and Group 4 medulloblastomas | Q34167499 | ||
| Enhancer hijacking activates GFI1 family oncogenes in medulloblastoma | Q34362028 | ||
| Histone deacetylase 8 in neuroblastoma tumorigenesis | Q34913307 | ||
| Sonic hedgehog-induced histone deacetylase activation is required for cerebellar granule precursor hyperplasia in medulloblastoma | Q34949592 | ||
| Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer | Q35758280 | ||
| Rapid, reliable, and reproducible molecular sub-grouping of clinical medulloblastoma samples | Q35837393 | ||
| Quantitative comparison of immunohistochemical staining measured by digital image analysis versus pathologist visual scoring | Q36048767 | ||
| Unraveling the hidden catalytic activity of vertebrate class IIa histone deacetylases | Q36141408 | ||
| Novel mutations target distinct subgroups of medulloblastoma. | Q36143877 | ||
| Epigenetic therapy using belinostat for patients with unresectable hepatocellular carcinoma: a multicenter phase I/II study with biomarker and pharmacokinetic analysis of tumors from patients in the Mayo Phase II Consortium and the Cancer Therapeuti | Q36222932 | ||
| Aberrant patterns of H3K4 and H3K27 histone lysine methylation occur across subgroups in medulloblastoma. | Q36631618 | ||
| Evaluation of romidepsin for clinical activity and radioactive iodine reuptake in radioactive iodine-refractory thyroid carcinoma | Q36813563 | ||
| Medulloblastoma comprises four distinct molecular variants | Q36920479 | ||
| Histone deacetylase 10 promotes autophagy-mediated cell survival. | Q37010515 | ||
| The regulatory role of c-MYC on HDAC2 and PcG expression in human multipotent stem cells | Q37295496 | ||
| MicroRNA-182 promotes leptomeningeal spread of non-sonic hedgehog-medulloblastoma. | Q53201641 | ||
| Phase I trial of MS-275, a histone deacetylase inhibitor, administered weekly in refractory solid tumors and lymphoid malignancies | Q81310348 | ||
| High-throughput detection and multiplex identification of cell contaminations | Q37393485 | ||
| Medulloblastomics: the end of the beginning | Q37469904 | ||
| Cytogenetic prognostication within medulloblastoma subgroups | Q37627692 | ||
| Belinostat: clinical applications in solid tumors and lymphoma | Q37951994 | ||
| The role of chromatin remodeling in medulloblastoma. | Q38083796 | ||
| Targeting of histone deacetylases in brain tumors. | Q38233117 | ||
| Decoding the regulatory landscape of medulloblastoma using DNA methylation sequencing | Q38993103 | ||
| GRHL1 acts as tumor suppressor in neuroblastoma and is negatively regulated by MYCN and HDAC3. | Q39034764 | ||
| MYCN and HDAC2 cooperate to repress miR-183 signaling in neuroblastoma | Q39158975 | ||
| HD-MB03 is a novel Group 3 medulloblastoma model demonstrating sensitivity to histone deacetylase inhibitor treatment. | Q39262034 | ||
| A novel human high-risk ependymoma stem cell model reveals the differentiation-inducing potential of the histone deacetylase inhibitor Vorinostat | Q39485541 | ||
| Diphenylmethylene hydroxamic acids as selective class IIa histone deacetylase inhibitors | Q39809571 | ||
| HKI 46F08, a novel potent histone deacetylase inhibitor, exhibits antitumoral activity against embryonic childhood cancer cells. | Q39944234 | ||
| Inhibitors of histone deacetylases as potential therapeutic tools for high-risk embryonal tumors of the nervous system of childhood | Q40182103 | ||
| Evaluation of the antitumor efficacy, pharmacokinetics, and pharmacodynamics of the histone deacetylase inhibitor depsipeptide in childhood cancer models in vivo | Q40333282 | ||
| MS-27-275, an inhibitor of histone deacetylase, has marked in vitro and in vivo antitumor activity against pediatric solid tumors | Q40692665 | ||
| Pimelic diphenylamide 106 is a slow, tight-binding inhibitor of class I histone deacetylases | Q42109512 | ||
| A proposal regarding reporting of in vitro testing results | Q42552338 | ||
| Robust molecular subgrouping and copy-number profiling of medulloblastoma from small amounts of archival tumour material using high-density DNA methylation arrays | Q43153279 | ||
| Nestin expression identifies ependymoma patients with poor outcome | Q43662312 | ||
| Antitumor effects of a combined 5-aza-2'deoxycytidine and valproic acid treatment on rhabdomyosarcoma and medulloblastoma in Ptch mutant mice | Q46156118 | ||
| Probing the elusive catalytic activity of vertebrate class IIa histone deacetylases | Q46727287 | ||
| HDAC5 and HDAC9 in medulloblastoma: novel markers for risk stratification and role in tumor cell growth | Q48227278 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P921 | main subject | medulloblastoma | Q1333608 |
| P304 | page(s) | 22 | |
| P577 | publication date | 2015-04-03 | |
| P1433 | published in | Acta Neuropathologica Communications | Q27724912 |
| P1476 | title | Targeting class I histone deacetylase 2 in MYC amplified group 3 medulloblastoma | |
| P478 | volume | 3 |
| Q60047613 | Application of Small Epigenetic Modulators in Pediatric Medulloblastoma |
| Q47900778 | Epigenetic regulation in medulloblastoma |
| Q37706929 | Establishment and application of a novel patient-derived KIAA1549:BRAF-driven pediatric pilocytic astrocytoma model for preclinical drug testing |
| Q38652681 | Evolving molecular era of childhood medulloblastoma: time to revisit therapy |
| Q36694288 | HDAC and PI3K Antagonists Cooperate to Inhibit Growth of MYC-Driven Medulloblastoma |
| Q33733042 | HDAC2 overexpression correlates with aggressive clinicopathological features and DNA-damage response pathway of breast cancer |
| Q37437368 | HDAC5, a potential therapeutic target and prognostic biomarker, promotes proliferation, invasion and migration in human breast cancer |
| Q38947405 | HDACs and HDAC Inhibitors in Cancer Development and Therapy |
| Q92382697 | Histone deacetylase inhibitors differentially regulate c-Myc expression in retinoblastoma cells |
| Q55022167 | Improved therapy for medulloblastoma: targeting hedgehog and PI3K-mTOR signaling pathways in combination with chemotherapy. |
| Q38791113 | Long term, continuous exposure to panobinostat induces terminal differentiation and long term survival in the TH-MYCN neuroblastoma mouse model |
| Q92534457 | MYC competes with MiT/TFE in regulating lysosomal biogenesis and autophagy through an epigenetic rheostat |
| Q91711195 | Methylation Profiling of Medulloblastoma in a Clinical Setting Permits Sub-classification and Reveals New Outcome Predictions |
| Q91842359 | Molecular characteristics and therapeutic vulnerabilities across paediatric solid tumours |
| Q41344917 | Panobinostat, a histone deacetylase inhibitor, suppresses leptomeningeal seeding in a medulloblastoma animal model |
| Q91863904 | Phase I/II intra-patient dose escalation study of vorinostat in children with relapsed solid tumor, lymphoma, or leukemia |
| Q36480084 | Preclinical studies of 5-fluoro-2'-deoxycytidine and tetrahydrouridine in pediatric brain tumors |
| Q36901551 | Risk stratification of childhood medulloblastoma in the molecular era: the current consensus |
| Q64389399 | The HDAC6/8/10 inhibitor TH34 induces DNA damage-mediated cell death in human high-grade neuroblastoma cell lines |
| Q36288376 | Uniformity under in vitro conditions: Changes in the phenotype of cancer cell lines derived from different medulloblastoma subgroups |
| Q38817974 | Viability of D283 medulloblastoma cells treated with a histone deacetylase inhibitor combined with bombesin receptor antagonists. |
| Q38957110 | Zinc and zinc-containing biomolecules in childhood brain tumors. |
Search more.